

**INVESTIGATOR DECLARATION  
Clinical Study Report**

Protocol Number: C4591001


Report Title: Interim Report – 6 Month Update: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

Clinical Lead: John L. Perez, MD, MBA, MA

Date of the Report: 29 April 2021

I, Dr. Stephen J. Thomas, the undersigned, have read the above-referenced clinical study report for study C4591001, which I have undertaken with Pfizer.

I confirm that to the best of my knowledge, it accurately describes the conduct and results of the study.



Signed:

Stephen J. Thomas, MD  
State University of New York  
Upstate Medical University

Date: 29 April 2021

The above lead investigator is acting as coordinator and signing on behalf of all centers involved in the above study.

090177e196ebc24e\Approved\Approved On: 30-Apr-2021 07:41 (GMT)